Induction of Trop-2 expression through the binding of galectin-3 to MUC1.

Biochem Biophys Res Commun

Department of Molecular Biosciences, Faculty of Life Sciences, Kyoto Sangyo University, Kyoto, 603-8555, Japan. Electronic address:

Published: August 2019


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Both mucin 1 (MUC1) and trophoblast cell surface antigen 2 (Trop-2) are overexpressed in various epithelial tumor cells, and their high expression is correlated with a poor prognosis. Both proteins were expressed in a human breast cancer cell line, MCF-7 cells, but neither was in a human colon cancer cell line, HCT116 cells. When MUC1 cDNA was introduced into HCT116 cells (HCT116/MUC1), expression of Trop-2 was induced. Reciprocally, treatment of MCF-7 cells with MUC1 siRNA reduced the level of Trop-2. Mithramycin A, an inhibitor of specificity protein 1 (Sp1) transcription factor, effectively inhibited the expression of Trop-2. Consistently, treatment with Sp1 siRNA reduced the expression of Trop-2. To reveal the relationship between MUC1 and Sp1, coimmunoprecipitation assays were performed. Sp1 was coimmunoprecipitated with MUC1 and the level of coimmunoprecipitated Sp1 increased in relation to the level of induced Trop-2. It is known that galectin-3 is an endogenous ligand of MUC1. Binding of galectin-3 to MUC1 elevated the recruitment of Sp1 to MUC1, and knockdown of galectin-3 reduced the level of Trop-2. These results suggest that the binding of galectin-3 to MUC1 enhances the recruitment of Sp1, leading to promotion of the transcription of Trop-2.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.06.003DOI Listing

Publication Analysis

Top Keywords

binding galectin-3
12
galectin-3 muc1
12
expression trop-2
12
muc1
10
trop-2
8
cancer cell
8
sirna reduced
8
reduced level
8
level trop-2
8
recruitment sp1
8

Similar Publications

Background: High % of low-voltage area (LVA), a surrogate of scar, is associated with atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI). Noninvasive biomarkers of LVA are a medical need for PVI decision.

Objective: We aimed to identify the proteome profile of plasma extracellular vesicles (EVs) associated with high % LVA, their cellular origin, and their regulation by hyperglycemia.

View Article and Find Full Text PDF

Premna microphylla Turcz pectin-modified diosmetin nanoparticles: A galectin-3 targeting strategy for precise colitis intervention.

Carbohydr Polym

November 2025

Shenzhen Key Laboratory of Food Nutrition and Health, College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, PR China. Electronic address:

Oral delivery of natural antioxidants represents a promising therapeutic strategy for ulcerative colitis (UC), yet their therapeutic efficacy is hindered by instability and poor accumulation at inflamed sites. To address this, we developed Galectin-3 (Gal-3)-targeted nanoparticles (ZDP-NPs) by encapsulating diosmetin within zein complexes modified with a galactose- and rhamnogalacturonan-I (RG-I)-rich pectin (PMTP, Mw: 228.8 kDa, DM: 34.

View Article and Find Full Text PDF

Chitinase-3-like 1 (CHI3L1) is a secreted glycoprotein implicated in carcinogenesis and tumor immune evasion. Elevated CHI3L1 expression is frequently detected in cancer patients, highlighting it as a promising therapeutic target. To overcome the limited availability of small molecule CHI3L1 inhibitors, we established a surface plasmon resonance (SPR)-based high-throughput screening platform and applied it to a focused chemical library of small molecules.

View Article and Find Full Text PDF

Diabetic foot ulcers are severe diabetic complications, and promoting impaired angiogenesis is essential for wound healing. Pro-angiogenic galectin-3 is elevated in diabetic serum and promotes systemic insulin resistance that may impair wound healing. However, the exact role of galectin-3 in the regulation of diabetic wound healing remains unclear.

View Article and Find Full Text PDF

Primary sclerosing cholangitis (PSC) occurs in approximately 25% of patients post-liver transplantation (LT) and is associated with significant morbidity and mortality. Hepatic duct cholestasis following recurrent PSC may lead to the development of liver cirrhosis and the need for liver retransplantation. To date, the exact etiology of the recurrence of PSC post-LT remains unknown, and it is not currently possible to predict which patients are at risk for recurrence of PSC.

View Article and Find Full Text PDF